ATYR
aTyr Pharma, Inc.
Healthcare · Biotechnology · NCM
$0.47
Data: 2026-05-13
✗ ETHICAL FAIL

MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$42M
Total market value of the company
Trailing P/E
0.00
Forward P/E
-1.08
Based on estimated future earnings — lower means cheaper
Rev Growth
0.0%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
ROE
-108.1%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$4.92
+946% from current price — median analyst estimate
Recommendation
HOLD
Consensus view from 6 analysts covering this stock
About aTyr Pharma, Inc.

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

https://atyrpharma.com

Country: United States Employees: 58 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
28.4% PASS
Debt must be below 33% of total assets
Cash Ratio
185.8% FAIL
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
DISTRIBUTION
Smart money appears to be selling into strength — caution
Sharpe Ratio
0.264
Positive but modest risk-adjusted returns
Kelly Fraction
0.0059
Marginal edge — very small allocation suggested
Calmar Ratio
-0.514
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-48.3%
Historical annualised return based on price data
Max Drawdown
-94.0%
Largest peak-to-trough decline — the worst it has been
HMM State
BEAR
Statistical model detects bearish conditions
Days in State
10
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
0.66
Less volatile than the market — more defensive
52W High
$7.29
94% below the year high
52W Low
$0.40
19% above the year low
Avg Volume
1,749,796
Average daily shares traded — higher means easier to buy and sell
Short Ratio
22.0
Days it would take all short sellers to cover — higher means more crowded
Short % Float
23.3%
Very high short interest — potential squeeze candidate
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-0.80
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.18
Conservative use of debt — low financial risk
Current Ratio
5.30
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
5.25
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
-40,856.3%
Profit from core operations before interest and tax
Free Cash Flow
$-33,797,876
Negative — the business is spending more than it generates
Revenue (TTM)
$190,000
Total revenue over the last 12 months
Net Income
$-74,118,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
6
Target High
$20.00
Target Median
$4.92
Target Low
$1.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2026-02-04 BROADFOOT JILL MARIE Chief Financial Officer 1,558 $1,521
2026-02-04 SHUKLA SANJAY S Chief Executive Officer 3,745 $3,655
2026-02-04 DENYES NANCY General Counsel 1,118 $1,091
2026-02-03 BROADFOOT JILL MARIE Chief Financial Officer 3,750 —
2026-02-03 SHUKLA SANJAY S Chief Executive Officer 10,375 —
2026-02-03 DENYES NANCY General Counsel 2,687 —
2025-10-09 SCHIMMEL PAUL R Director 1,000,000 $911,801
2025-03-17 GROSS JANE A Director 3,750 $15,000
2025-02-04 BROADFOOT JILL MARIE Chief Financial Officer 1,254 $4,740
2025-02-04 DENYES NANCY General Counsel 899 $3,398
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-13

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.